Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gedske Daugaard, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT00269373
First received: December 22, 2005
Last updated: February 20, 2012
Last verified: February 2012
  Purpose

Is PET-CT scan better than PET or CT alone in diagnosing primary tumours in patients with unknown primary tumors? Can information obtained with PET-CT replace other clinical and radiological investigations? Is PET/CT cost-effective?


Condition Intervention
Unknown Primary Tumor
Procedure: PET-CT

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: PET-CT Scan as a Diagnostic Method in Unknown Primary Tumors

Resource links provided by NLM:


Further study details as provided by Rigshospitalet, Denmark:

Enrollment: 136
Study Start Date: December 2005
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: PET-CT
    no drugs included
Detailed Description:

Patients who fulfill the international definition of unknown primary tumors can be included, except:

  • Young men (<55 years) with growing mid-line tumors where a germ cell tumor could be expected will not be included.
  • Patients with lymph-node metastases with squamous cell carcinoma in the head and neck region will not be included.
  • Women with adenocarcinoma in lymph nodes in the axilla will not be included.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with unknown tumors

Criteria

Inclusion Criteria:

  • Unknown primary tumors

Exclusion Criteria:

  • Young men (<55 years) with growing mid-line tumors where a germ cell tumor could be expected will not be included.
  • Patients with lymph-node metastases with squamous cell carcinoma in the head and neck region will not be included
  • Women with adenocarcinoma in lymph nodes in the axilla will not be included
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00269373

Locations
Denmark
Rigshospitalet
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Investigators
Principal Investigator: Gedske Daugaard Rigshospitalet, Denmark
  More Information

No publications provided

Responsible Party: Gedske Daugaard, Associate professor, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT00269373     History of Changes
Other Study ID Numbers: 01 283694
Study First Received: December 22, 2005
Last Updated: February 20, 2012
Health Authority: Denmark: Ethics Committee

Keywords provided by Rigshospitalet, Denmark:
Unknown primary tumor
PET-CT

Additional relevant MeSH terms:
Neoplasms, Unknown Primary
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes

ClinicalTrials.gov processed this record on August 27, 2014